论文部分内容阅读
虽然应用有力的常规治疗(同化激素、肾上腺皮质激素、输血及抗菌素等),至到目前再生障碍性贫血(简称再障)的预后还很不佳,有些病例可能缓解或恢复,但中数生存时间只有3～6月,严重再障中数生存时间仅82天。用骨髓移植(简称BmT)治疗再障已有40余年,但过去都持否定态度。Bortin回顾了1964年以前200例BmT治疗本病的结果,发现输给异体骨髓细胞者无一例存活。近几年来,由于选择组织配型相合的近亲,移植前后的精心准备与严密观察,同种骨髓移植病例中约有半数病例长期存活,Thomas报告三例同卵双胎BmT已存活16年,当前长期存活者已超过100例,预后有所改观。现将BmT治疗再障中的几个问题综述如下:
Although the use of potent routine therapies (anabolic hormones, adrenal cortical hormones, blood transfusions, antibiotics, etc.), the prognosis of aplastic anemia (aplastic anemia) is still poor at present, some cases may be alleviated or recovered, but the median survival Time is only 3 to 6 months, severe aplastic anemia in the survival time of only 82 days. Bone marrow transplantation (referred to as BmT) aplastic anemia treatment for more than 40 years, but in the past are negative. Bortin reviewed the results of 200 BmT treatments of the disease prior to 1964 and found no survival in allogeneic myeloid cells. In recent years, Thomas has reported that three identical twins have survived for 16 years due to the long-term survival of approximately half of all cases of allogeneic bone marrow transplantation due to careful selection and close observation before and after transplantation. Long-term survivors have more than 100 cases, the prognosis has changed. Now BmT treatment of aplastic anemia in a few questions are summarized as follows: